Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Article
  • Published:

Tau modification by the norepinephrine metabolite DOPEGAL stimulates its pathology and propagation

Nature Structural & Molecular Biology volume 29, pages 292–305 (2022)Cite this article

Subjects

Abstract

The noradrenergic locus ceruleus (LC) is the first site of detectable tau pathology in Alzheimer’s disease (AD), but the mechanisms underlying the selective vulnerability of the LC in AD have not been completely identified. In the present study, we show that DOPEGAL, a monoamine oxidase A (MAO-A) metabolite of norepinephrine (NE), reacts directly with the primary amine on the Lys353 residue of tau to stimulate its aggregation and facilitate its propagation. Inhibition of MAO-A or mutation of the Lys353 residue to arginine (Lys353Arg) decreases tau Lys353–DOPEGAL levels and diminishes tau pathology spreading. Wild-type tau preformed fibrils (PFFs) trigger Lys353–DOPEGAL formation, tau pathology propagation and cognitive impairment in MAPT transgenic mice, all of which are attenuated with PFFs made from the Lys353Arg mutant. Thus, the selective vulnerability of LC neurons in AD may be explained, in part, by NE oxidation via MAO-A into DOPEGAL, which covalently modifies tau and accelerates its aggregation, toxicity and propagation.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on SpringerLink
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Fig. 1: DOPEGAL modifies tau Lys353 residue and mediates tau aggregation.
Fig. 2: DOPEGAL modification of tau promotes its aggregation and seeding.
Fig. 3: Tau modification by DOPEGAL induces AEP activation, tau pathology and cell death in neurons.
Fig. 4: DOPEGAL is upregulated and modifies tau at Lys353 in the progression of AD.
Fig. 5: Inhibition of MAO-A reduces DOPEGAL-tau modification and tau pathology in tau P301S mice.
Fig. 6: Lys353Arg mutation is unable to initiate or propagate tau pathology and memory dysfunctions in tau−/− mice.
Fig. 7: Mutation of Lys353Arg is resistant to tau fibrillization and propagation in MAPT mouse brain.

Similar content being viewed by others

Data availability

The authors declare that all data supporting the findings of the present study are available within the article and Source data files. Source data are provided with this paper.

References

  1. Grundke-Iqbal, I. et al. Abnormal phosphorylation of the microtubule-associated protein tau (tau) in Alzheimer cytoskeletal pathology. Proc. Natl Acad. Sci. USA 83, 4913–4917 (1986).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  2. Braak, H. & Braak, E. Neuropathological stageing of Alzheimer-related changes. Acta Neuropathol. 82, 239–259 (1991).

    Article  CAS  PubMed  Google Scholar 

  3. Arriagada, P. V., Growdon, J. H., Hedley-Whyte, E. T. & Hyman, B. T. Neurofibrillary tangles but not senile plaques parallel duration and severity of Alzheimer’s disease. Neurology 42, 631–639 (1992).

    Article  CAS  PubMed  Google Scholar 

  4. Cho, H. et al. Tau PET in Alzheimer disease and mild cognitive impairment. Neurology 87, 375–383 (2016).

    Article  CAS  PubMed  Google Scholar 

  5. Weinshenker, D. Functional consequences of locus coeruleus degeneration in Alzheimer’s disease. Curr. Alzheimer Res. 5, 342–345 (2008).

    Article  CAS  PubMed  Google Scholar 

  6. Chalermpalanupap, T. et al. Targeting norepinephrine in mild cognitive impairment and Alzheimer’s disease. Alzheimers Res. Ther. 5, 21 (2013).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  7. Rorabaugh, J. M. et al. Chemogenetic locus coeruleus activation restores reversal learning in a rat model of Alzheimer’s disease. Brain 140, 3023–3038 (2017).

    Article  PubMed  PubMed Central  Google Scholar 

  8. Ressler, K. J. & Nemeroff, C. B. Role of norepinephrine in the pathophysiology and treatment of mood disorders. Biol. Psychiatry 46, 1219–1233 (1999).

    Article  CAS  PubMed  Google Scholar 

  9. Sara, S. J. The locus coeruleus and noradrenergic modulation of cognition. Nat. Rev. Neurosci. 10, 211–223 (2009).

    Article  CAS  PubMed  Google Scholar 

  10. Herrmann, N., Lanctôt, K. L. & Khan, L. R. The role of norepinephrine in the behavioral and psychological symptoms of dementia. J. Neuropsychiatry Clin. Neurosci. 16, 261 (2004).

    Article  CAS  PubMed  Google Scholar 

  11. Theofilas, P., Dunlop, S., Heinsen, H. & Grinberg, L. T. Turning on the light within: subcortical nuclei of the isodentritic core and their role in Alzheimer’s disease pathogenesis. J. Alzheimers Dis. 46, 17–34 (2015).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  12. Theofilas, P. et al. Locus coeruleus volume and cell population changes during Alzheimer’s disease progression: a stereological study in human postmortem brains with potential implication for early-stage biomarker discovery. Alzheimers Dement. 13, 236–246 (2017).

    Article  PubMed  Google Scholar 

  13. Rüb, U. et al. The brainstem tau cytoskeletal pathology of Alzheimer’s disease: a brief historical overview and description of its anatomical distribution pattern, evolutional features, pathogenetic and clinical relevance. Curr. Alzheimer Res. 13, 1178–1197 (2016).

    Article  CAS  PubMed  Google Scholar 

  14. Chalermpalanupap, T., Schroeder, J. P., Rorabaugh, J. M., Liles, L. C. & Lah, J. J. Locus coeruleus ablation exacerbates cognitive deficits, neuropathology, and lethality in P301S tau transgenic mice. J. Neurosci. 38, 74–92 (2018).

  15. Wischik, C. M., Harrington, C. R. & Storey, J. M. Tau-aggregation inhibitor therapy for Alzheimer’s disease. Biochem Pharm. 88, 529–539 (2014).

    Article  CAS  PubMed  Google Scholar 

  16. Kelly, S. C. et al. Locus coeruleus cellular and molecular pathology during the progression of Alzheimer’s disease. Acta Neuropathol. Commun. 5, 8 (2017).

    Article  PubMed  PubMed Central  Google Scholar 

  17. Mattammal, M. B., Strong, R., Lakshmi, V. M., Chung, H. D. & Stephenson, A. H. Prostaglandin H synthetase-mediated metabolism of dopamine: implication for Parkinson’s disease. J. Neurochem. 64, 1645–1654 (1995).

    Article  CAS  PubMed  Google Scholar 

  18. Burke, W. J. 3,4-Dihydroxyphenylacetaldehyde: a potential target for neuroprotective therapy in Parkinson’s disease. Curr. Drug Targets CNS Neurol. Disord. 2, 143–148 (2003).

    Article  CAS  PubMed  Google Scholar 

  19. Li, S. W., Lin, T. S., Minteer, S. & Burke, W. J. 3,4-Dihydroxyphenylacetaldehyde and hydrogen peroxide generate a hydroxyl radical: possible role in Parkinson’s disease pathogenesis. Brain Res. Mol. Brain Res. 93, 1–7 (2001).

    Article  CAS  PubMed  Google Scholar 

  20. Eisenhofer, G., Kopin, I. J. & Goldstein, D. S. Catecholamine metabolism: a contemporary view with implications for physiology and medicine. Pharm. Rev. 56, 331–349 (2004).

    Article  CAS  PubMed  Google Scholar 

  21. Burke, W. J. et al. Accumulation of 3,4-dihydroxyphenylglycolaldehyde, the neurotoxic monoamine oxidase A metabolite of norepinephrine, in locus ceruleus cell bodies in Alzheimer’s disease: mechanism of neuron death. Brain Res. 816, 633–637 (1999).

    Article  CAS  PubMed  Google Scholar 

  22. Burke, W. J. et al. Neurotoxicity of MAO metabolites of catecholamine neurotransmitters: role in neurodegenerative diseases. Neurotoxicology 25, 101–115 (2004).

    Article  CAS  PubMed  Google Scholar 

  23. Burke, W. J., Kristal, B. S., Yu, B. P., Li, S. W. & Lin, T. S. Norepinephrine transmitter metabolite generates free radicals and activates mitochondrial permeability transition: a mechanism for DOPEGAL-induced apoptosis. Brain Res. 787, 328–332 (1998).

    Article  CAS  PubMed  Google Scholar 

  24. Kristal, B. S. et al. Selective dopaminergic vulnerability: 3,4-dihydroxyphenylacetaldehyde targets mitochondria. Free Radic. Biol. Med. 30, 924–931 (2001).

    Article  CAS  PubMed  Google Scholar 

  25. Burke, W. J., Schmitt, C. A., Gillespie, K. N. & Li, S. W. Norepinephrine transmitter metabolite is a selective cell death messenger in differentiated rat pheochromocytoma cells. Brain Res. 722, 232–235 (1996).

    Article  CAS  PubMed  Google Scholar 

  26. Burke, W. J. et al. Catecholamine monoamine oxidase a metabolite in adrenergic neurons is cytotoxic in vivo. Brain Res 891, 218–227 (2001).

    Article  CAS  PubMed  Google Scholar 

  27. Zhang, Z. et al. Cleavage of tau by asparagine endopeptidase mediates the neurofibrillary pathology in Alzheimer’s disease. Nat. Med. 20, 1254–1262 (2014).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  28. Zhang, Z. et al. Delta-secretase cleaves amyloid precursor protein and regulates the pathogenesis in Alzheimer’s disease. Nat. Commun. 6, 8762 (2015).

    Article  CAS  PubMed  Google Scholar 

  29. Kang, S. S. et al. α-Synuclein stimulation of monoamine oxidase-B and legumain protease mediates the pathology of Parkinson’s disease. EMBO J. 37, e98878 (2018).

  30. Kang, S. S. et al. Norepinephrine metabolite DOPEGAL activates AEP and pathological Tau aggregation in locus coeruleus. J. Clin. Invest. 130, 422–437 (2020).

    Article  CAS  PubMed  Google Scholar 

  31. Kang, S. S. et al. ApoE4 inhibition of VMAT2 in the locus coeruleus exacerbates Tau pathology in Alzheimer’s disease. Acta Neuropathol. https://doi.org/10.1007/s00401-021-02315-1 (2021).

  32. Cook, C. et al. Acetylation of the KXGS motifs in tau is a critical determinant in modulation of tau aggregation and clearance. Hum. Mol. Genet. 23, 104–116 (2014).

    Article  CAS  PubMed  Google Scholar 

  33. Leuzy, A. et al. Longitudinal tau and metabolic PET imaging in relation to novel CSF tau measures in Alzheimer’s disease. Eur. J. Nucl. Med. Mol. Imaging 46, 1152–1163 (2019).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  34. Blennow, K. et al. Cerebrospinal fluid tau fragment correlates with tau PET: a candidate biomarker for tangle pathology. Brain 143, 650–660 (2020).

    Article  PubMed  Google Scholar 

  35. Zhang, Z. et al. Asparagine endopeptidase cleaves α-synuclein and mediates pathologic activities in Parkinson’s disease. Nat. Struct. Mol. Biol. 24, 632–642 (2017).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  36. Sayre, L. M., Smith, M. A. & Perry, G. Chemistry and biochemistry of oxidative stress in neurodegenerative disease. Curr. Med Chem. 8, 721–738 (2001).

    Article  CAS  PubMed  Google Scholar 

  37. Marchitti, S. A., Deitrich, R. A. & Vasiliou, V. Neurotoxicity and metabolism of the catecholamine-derived 3,4-dihydroxyphenylacetaldehyde and 3,4-dihydroxyphenylglycolaldehyde: the role of aldehyde dehydrogenase. Pharm. Rev. 59, 125–150 (2007).

    Article  CAS  PubMed  Google Scholar 

  38. Tuma, D. J., Donohue, T. M. Jr., Medina, V. A. & Sorrell, M. F. Enhancement of acetaldehyde-protein adduct formation by l-ascorbate. Arch. Biochem. Biophys. 234, 377–381 (1984).

    Article  CAS  PubMed  Google Scholar 

  39. Cheng, Y. & Bai, F. The association of tau with mitochondrial dysfunction in Alzheimer’s disease. Front. Neurosci. 12, 163 (2018).

    Article  PubMed  PubMed Central  Google Scholar 

  40. Mandelkow, E. M., Stamer, K., Vogel, R., Thies, E. & Mandelkow, E. Clogging of axons by tau, inhibition of axonal traffic and starvation of synapses. Neurobiol. Aging 24, 1079–1085 (2003).

    Article  CAS  PubMed  Google Scholar 

  41. Hu, Y. et al. Tau accumulation impairs mitophagy via increasing mitochondrial membrane potential and reducing mitochondrial Parkin. Oncotarget 7, 17356–17368 (2016).

    Article  PubMed  PubMed Central  Google Scholar 

  42. Li, X. C. et al. Human wild-type full-length tau accumulation disrupts mitochondrial dynamics and the functions via increasing mitofusins. Sci. Rep. 6, 24756 (2016).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  43. Jucker, M. & Walker, L. C. Pathogenic protein seeding in Alzheimer disease and other neurodegenerative disorders. Ann. Neurol. 70, 532–540 (2011).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  44. Gibbons, G. S., Lee, V. M. Y. & Trojanowski, J. Q. Mechanisms of cell-to-cell transmission of pathological tau: a review. JAMA Neurol. 76, 101–108 (2019).

    Article  PubMed  PubMed Central  Google Scholar 

  45. Bell, B. J., Malvankar, M. M., Tallon, C. & Slusher, B. S. Sowing the seeds of discovery: tau-propagation models of Alzheimer’s disease. ACS Chem. Neurosci. 11, 3499–3509 (2020).

    Article  CAS  PubMed  Google Scholar 

  46. Asai, H. et al. Depletion of microglia and inhibition of exosome synthesis halt tau propagation. Nat. Neurosci. 18, 1584–1593 (2015).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  47. Wegmann, S. et al. Removing endogenous tau does not prevent tau propagation yet reduces its neurotoxicity. EMBO J. 34, 3028–3041 (2015).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  48. Heneka, M. T. et al. Locus ceruleus degeneration promotes Alzheimer pathogenesis in amyloid precursor protein 23 transgenic mice. J. Neurosci. 26, 1343–1354 (2006).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  49. Hammerschmidt, T. et al. Selective loss of noradrenaline exacerbates early cognitive dysfunction and synaptic deficits in APP/PS1 mice. Biol. Psychiatry 73, 454–463 (2013).

    Article  CAS  PubMed  Google Scholar 

  50. Weinshenker, D. Long road to ruin: noradrenergic dysfunction in neurodegenerative disease. Trends Neurosci. 41, 211–223 (2018).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  51. Heneka, M. T. et al. Locus ceruleus controls Alzheimer’s disease pathology by modulating microglial functions through norepinephrine. Proc. Natl Acad. Sci. USA 107, 6058–6063 (2010).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  52. Yu, K. et al. High-throughput profiling of proteome and posttranslational modifications by 16-Plex TMT labeling and mass spectrometry. Methods Mol. Biol. 2228, 205–224 (2021).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  53. Ma, B. et al. PEAKS: powerful software for peptide de novo sequencing by tandem mass spectrometry. Rapid Commun. Mass Spectrom. 17, 2337–2342 (2003).

    Article  CAS  PubMed  Google Scholar 

Download references

Acknowledgements

We thank the Emory Goizueta Alzheimer’s Disease Research Center for postmortem human AD and healthy control samples. This work was supported by the National Institutes for Health (NIH; grant no. RF1 AG061175 to S.S.K. and D.W.), the National Natural Science Foundation of China (grant no. 81822016 to Z.Z.) and the National Key Basic Research Program of China Grant (grant no, 2019YFE0115900 to Z.Z.). Additional support was provided by the Emory Neuroscience National Institute of Neurological Disorders Core Facilities (grant no. P30NS055077). Further support was provided by the Georgia Clinical & Translational Science Alliance of the NIH under award no. UL1TR002378. The present study was supported in part by the Rodent Behavioral Core, Viral Vector Core and HPLC Bioanalytical Core, which are subsidized by the Emory University School of Medicine and are part of the Emory Integrated Core Facilities.

Author information

Authors and Affiliations

  1. Department of Pathology and Laboratory Medicine, Emory University School of Medicine, Atlanta, GA, USA

    Seong Su Kang, Xia Liu & Keqiang Ye

  2. Department of Neurology, Renmin Hospital of Wuhan University, Wuhan, China

    Lanxia Meng, Xingyu Zhang & Zhentao Zhang

  3. Departments of Structural Biology and Developmental Neurobiology, St. Jude Children’s Research Hospital, Memphis, TN, USA

    Zhiping Wu, Ariana Mancieri, Boer Xie & Junmin Peng

  4. Center for Proteomics and Metabolomics, St. Jude Children’s Research Hospital, Memphis, TN, USA

    Zhiping Wu, Ariana Mancieri, Boer Xie & Junmin Peng

  5. Department of Human Genetics, Emory University School of Medicine, Atlanta, GA, USA

    David Weinshenker

  6. Faculty of Life and Health Sciences, Shenzhen Institute of Advanced Technology, Shenzhen, China

    Keqiang Ye

  7. The Brain Cognition and Brain Disease Institute, Shenzhen Institute of Advanced Technology, Shenzhen, China

    Keqiang Ye

Authors
  1. Seong Su Kang
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Lanxia Meng
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Xingyu Zhang
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Zhiping Wu
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Ariana Mancieri
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Boer Xie
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Xia Liu
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. David Weinshenker
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Junmin Peng
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. Zhentao Zhang
    View author publications

    You can also search for this author in PubMed Google Scholar

  11. Keqiang Ye
    View author publications

    You can also search for this author in PubMed Google Scholar

Contributions

K.Y. and Z.Z. conceived the project, designed the experiments and analyzed the data. K.Y. wrote the manuscript. S.S.K. designed and performed most of the experiments and analyzed the data. X.L. prepared primary neurons and assisted with animal experiments. L.M. and X.Z. performed tau fibrillation in vitro experiments. Z.W., A.M. and J.P. performed LC–MS/MS experiments and assisted data analysis. D.W. helped design the experiments and edited the manuscript.

Corresponding authors

Correspondence to Zhentao Zhang or Keqiang Ye.

Ethics declarations

Competing interests

The authors have declared that no conflict of interests exists.

Peer review

Peer review information

Nature Structural and Molecular Biology thanks the anonymous reviewers for their contribution to the peer review of this work. Editor recognition statement: Florian Ullrich was the primary editor on this article and managed its editorial process and peer review in collaboration with the rest of the editorial team. Peer reviewer reports are available.

Additional information

Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Extended data

Extended Data Fig. 1 Biophysical characterization of recombinant Tau and Tau K353R mutant fibrils.

A. X-ray diffraction assay demonstrating characters of fibrils generated from Tau, Tau K353R, Tau N368, and Tau N368 K353R protein. B. Quantification table showed that DOPEGAL increased the counts of β-sheet at around 4.8 Å for Tau and Tau N368, but not Tau K353R and Tau N368 K353R. C. LC-MS/MS spectrum confirming DOPEGAL-modified Tau residue at K353 by the application of GluC digestion for the protein samples. D. Recombinant wild-type and K353R Tau were induced to aggregate into PFFs in the presence or absence of DOPEGAL. The PFFs were digested with Protease K (2 μg/ml). All data are representatives of three independent experiments with similar results. E. Recombinant Tau and Tau N368 were incubated with DOPEGAL (500 μM) for 0, 5, 30, and 60 minutes. Western blot and densitometric quantification of TauK353-DOPEGAL band showed that Tau N368 is more prone to be modified by DOPEGAL than full-length Tau. All data are shown as mean ± SEM. n = 3 per group. Paired Student t-test.

Source data

Extended Data Fig. 2 DOPEGAL promotes tau aggregation, attenuated by Tau K353R mutation.

A. Representative images showing the co-localization of aggregated tau with ubiquitin in tau PFF-treated HEK293 cells stably transfected with GFP-Tau RD in the presence or absence of DOPEGAL. Scale bar is 20 μm. B. HEK293 cells were transfected with wild-type or K353R mutant Tau RD, treated with DOPEGAL, and then transduced with tau PFFs. The green dots show tau inclusions. Scale bar is 20 μm. C. Quantification of the percentage of cells with tau inclusions. Data are shown as mean ± SEM. n = 10 per group. One-way ANOVA. D. The cells were sequentially extracted with 1% Triton X-100 lysis buffer followed by 2% SDS. Cell lysates from Triton X-100 soluble and SDS-soluble fractions were immunoblotted with GFP antibody. E. Quantification of the relative concentration of tau in the Triton X-100 soluble and SDS-soluble fractions. Data are shown as mean ± SEM. n = 4 per group. One-way ANOVA. F. The HEK293 cells stably transfected with GFP-Tau RD were exposed to DOPEGAL. The phosphorylation of tau at S202 was analyzed by immunofluorescence (red) and western blot. All data and images are representatives of three independent experiments with similar results.

Source data

Extended Data Fig. 3 DOPEGAL modification at Tau K353 is dependent on NE.

Tau P301S/DBH + /- and Tau P301S/DBH-/- mice of 3 months and 9 months old were examined for DOPEGAL modification and phosphorylation of Tau in the LC by immunofluorescence staining. A. Representative images of DBH (green), Tau K353-DOPEGAL (red), and DAPI (blue), AT8 (green), Tau K353-DOPEGAL (red), and DAPI (blue) staining in LC sections of Tau P301S/DBH + /- and Tau P301S/DBH-/- mice. Scale bar = 100 μm. B. Quantification of Tau K353-DOPEGAL/AT8 + cells. Data are shown as mean ± SEM. n = 6 per group. Two-way ANOVA with Sidak’s multiple comparison.

Source data

Extended Data Fig. 4 DOPEGAL modification of Tau is regulated by AEP and MAO-A.

DOPEGAL (0.25 μg) was injected into the LC regions of MAPT and MAPT/AEP-/- mice. DOPEGAL modification and cleavage of Tau in the LC were examined by immunofluorescence staining. A. Representative images of DBH (green), TauK353-DOPEGAL (red), and DAPI (blue); Tau N368 (green), TauK353-DOPEGAL (red), and DAPI (blue) staining in LC sections of DOPEGAL-injected MAPT and MAPT/AEP-/- mice. Scale bar is 100 μm. B,C. Quantification of TauK353-DOPEGAL + (B) and Tau N368 + cells (C). Data are shown as mean ± SEM. n = 6 per group. Two-way ANOVA with Sidak’s multiple comparison. D. AAV-control or AAV-MAO-A was injected into the LC regions of MAPT mice. Neuronal cell death (TUNEL) and DOPEGAL modification (Tau K353-DOPEGAL), cleavage (Tau N368), phosphorylation (AT8), and aggregation (T22) of Tau in the LC were examined by immunofluorescence staining. Scale bar is 100 μm. E. Co-stained positive cells were quantified in the LC of AAV-injected MAPT mice. Data are shown as mean ± SEM. n = 6 per group. Student t-test.

Source data

Extended Data Fig. 5 Inhibition of MAO-A reduces DOPEGAL-Tau modification and Tau pathology in P301S mice.

MAO-A inhibitor clorgyline was administered in 3-month-old tau P301S mice for 3 months (3 mg/kg/day). A,B. Representative images of immunofluorescent staining for Tau K353-DOPEGAL (green), Tau N368 (red), and DAPI (blue) (A) and Tau K353-DOPEGAL (green); AT8 (red); DAPI (blue) (B). Scale bars are 100 μm (left) and 20 μm (right). C. Quantification of Tau K353-DOPEGAL/TauN368+ and Tau K353-DOPEGAL/AT8 + cells in the LC sections of vehicle- or clorgyline-treated Tau P301S mice. Data are shown as mean ± SEM. n = 6 mice per group. Student t-test.

Source data

Extended Data Fig. 6 Tau K353R mutation blocks tau pathology spreading from the LC to the forebrain in Tau -/- mice.

AAV-control, AAV-Tau, and AAV-Tau K353R were injected into the LC of 3-month-old Tau -/- mice. The mice were assessed for Tau cleavage and phosphorylation 3 months after injection. A,B. Representative images of immunofluorescent staining for Tau K353-DOPEGAL (green); Tau N368 (red); DAPI (blue) (A) and Tau K353-DOPEGAL (green); AT8 (red); DAPI (blue) (B). Scale bars are 100 μm (left) and 20 μm (right). C. Quantification of Tau N368 + and AT8 + cells in the LC sections. Data are shown as mean ± SEM. n = 6 mice per group. Two-way ANOVA with Sidak’s multiple comparison. D. Quantitative PCR demonstrating the expression of human Tau in LC, EC, and HC at 3 months after viral injection. Data are shown as mean ± SEM. n = 4. Two-way ANOVA with Sidak’s multiple comparison. E. Representative images of immunohistochemistry staining for Tau K353-DOPEGAL on the LC, EC, and HC sections at 1 month after AAV-Tau injection into LC of Tau-/- mice. Scale bar is 200 μm. F. K353-DOPEGAL/NeuN or K353-DOPEGAL/DBH immunofluorescent co-staining on the EC or HC of Tau -/- mice. Tau K353-DOPEGAL (green)/NeuN or DBH (red); Tau K353-DOPEGAL (red)/ DBH (green)/DAPI (blue). Scale bar is100 μm. All images of E & F are representatives of three independent experiments with similar results.

Source data

Extended Data Fig. 7 Tau PFFs fail to induce tau pathology in Tau-/- mice.

Pre-formed fibrils (PFFs) of Tau or Tau K353R were injected into the LC of 3-month-old Tau -/- mice. The mice were assessed for DOPEGAL modification and phosphorylation of Tau 3 months later. A, B. Representative images of immunofluorescent staining for Tau K353-DOPEGAL (red); DBH (green); DAPI (blue) (A) and Tau K353-DOPEGAL (green); AT8 (red); DAPI (blue) (B). Scale bars are 100 μm (left) and 20 μm (right). C. Quantification of DBH + cells in the LC sections of PBS, Tau, or Tau K353R PFFs-injected Tau-/- mice. Data are shown as mean ± SEM. n = 8 per group. One-way ANOVA. D. Quantification of Tau K353-DOPEGAL + and AT8 + cells in the LC sections of PFFs-injected Tau -/- mice. Data are shown as mean ± SEM. n = 6 per group. Two-way ANOVA with Sidak’s multiple comparison.

Source data

Supplementary information

Source data

Source Data Fig. 1

Unprocessed western blots.

Source Data Fig. 1

Statistical source data.

Source Data Fig. 2

Unprocessed western blots.

Source Data Fig. 2

Statistical source data.

Source Data Fig. 3

Unprocessed western blots.

Source Data Fig. 3

Statistical source data.

Source Data Fig. 4

Unprocessed western blots.

Source Data Fig. 4

Statistical source data.

Source Data Fig. 5

Statistical source data.

Source Data Fig. 6

Statistical source data.

Source Data Fig. 7

Statistical source data.

Source Data Extended Data Fig. 1

Unprocessed western blots.

Source Data Extended Data Fig. 1

Statistical source data.

Source Data Extended Data Fig. 2

Unprocessed western blots.

Source Data Extended Data Fig. 2

Statistical source data.

Source Data Extended Data Fig. 3

Statistical source data.

Source Data Extended Data Fig. 4

Statistical source data.

Source Data Extended Data Fig. 5

Statistical source data.

Source Data Extended Data Fig. 6

Statistical source data.

Source Data Extended Data Fig. 7

Statistical source data.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Kang, S.S., Meng, L., Zhang, X. et al. Tau modification by the norepinephrine metabolite DOPEGAL stimulates its pathology and propagation. Nat Struct Mol Biol 29, 292–305 (2022). https://doi.org/10.1038/s41594-022-00745-3

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/s41594-022-00745-3

This article is cited by

Search

Advanced search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing